News

Reel change after change of scene
Enlarge image

BiopeopleUKAustria

Reel change after change of scene

15.05.2012 - F-Star's management has been lifted and replaced by a troika of new leaders.

Cambridge  - A press note issued by Austrian-British F-Star GmbH on 14 May names the new personnel. Following Keith Fitz-Gerald as CEO is John Haurum who had been CSO of the Danish biotechnology company Symphogen A/S. Also quickly appointed: Jane Dancer and Sharon Grimster. Dancer was previously employed at Cellzome Ltd. At F-Star she becomes Chief Operating Officer (COO).  Grimster, formerly employed at Antisoma plc, has been appointed Vice President of Development.

Clearing the management board so vigorously  is indeed a surprise, even with the knowledge that the company - a leader in the development of bispecific antibodies - has had a hard time after moving all research operations from Vienna to Cambridge leaving the parent company in Austria. The Supervisory Board did not forget to mention Kevin FitzGerald and thanked him for "his significant contribution in bringing F-star to its current stage of development". He started as the company's CEO in May 2009. Within this three years, the start-up saved €23m using venture financing. He also arranged major alliances with Boehringer Ingelheim and Merck Serono.


With its proprietary technology, F-star produces antibody fragments called Fcabs, which have full antibody capabilities but are believed to have a better biological profile because of their small size. Additionally Fcabs may offer IP advantages in many cases by lacking variable regions, which may be claimed by third party antibody patents. This seems to attract pharma companies. In November 2010, F-star allied with Germany's Boehringer Ingelheim and in September 2011 with Merck Serono.

http://www.european-biotechnology-news.com/news/news/2012-02/reel-change-after-change-of-scene.html

ResearchUKSwitzerlandItaly

29.08.2014 Just a week ago, Glaxosmithkline defused the WHO’s claim that an Ebola vaccine could be ready by 2015. Now, the British company’s own candidate vaccine is to be rushed to human trials with the help of funding from an international consortium.

BusinessGermany

24.08.2014 Germany's Morphosys is licensing a preclinical bi-specific antibody for the treatment of prostate cancer from Emergent Biosolutions. The US developer will rake in up to €138m for the commercialisation rights to the compound.

BusinessUK

20.08.2014 Biopharmaceutical contract manufacturer Fujifilm Diosynth Biotechnologies is expanding its cell culture manufacturing capacity further with a new 2,000l single-use bioreactor at the company’s site in Billingham, UK.

BusinessEUGermanyUK

15.08.2014 Some of Europe’s biggest pharma companies are competing in a bidding war for US biotech Intermune Inc., Bloomberg reports, citing insider reports as the source.

ResearchEUGermanyUK

13.08.2014 The Ebola epidemic is still raging on in West Africa and thus far there is

neither vaccine nor cure for the viral disease. The only flickers of hope:

an experimental antibody serum and an early-stage vaccine.

BusinessFrance

11.08.2014 Will Sanofi succeed where Pfizer failed? The French pharmaceutical company has taken on the commercialisation of Mannkind Corporation’s inhaled insulin product Afrezza.

ResearchSwedenGermany

08.08.2014 Boehringer Ingelheim is walking away from Swedish Orexo's prostaglandin inhibition project OX-MPI. Germany's largest researching pharmaceutical company had been responsible for the project's research and development since 2005.

ResearchSwitzerlandDenmark

06.08.2014 Roche is re-expanding its involvement in RNAi technologies. The Swiss pharmaceutical company will pay up to €335m for the acquisition of the Danish company Santaris Pharma A/S.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • WILEX2.40 EUR6.67%
  • SANTHERA100.10 CHF1.78%
  • ACTELION112.70 CHF1.35%

FLOP

  • THERAMETRICS0.07 CHF-12.50%
  • VITA 343.70 EUR-5.85%
  • EVOTEC3.68 EUR-1.60%

TOP

  • SANTHERA100.10 CHF67.1%
  • BB BIOTECH142.65 EUR10.2%
  • MAGFORCE6.80 EUR6.1%

FLOP

  • MOLOGEN7.31 EUR-14.0%
  • THERAMETRICS0.07 CHF-12.5%
  • VITA 343.70 EUR-11.1%

TOP

  • SANTHERA100.10 CHF4388.8%
  • CO.DON2.51 EUR213.7%
  • PAION2.43 EUR173.0%

FLOP

  • CYTOS0.25 CHF-93.7%
  • MEDIGENE4.53 EUR-67.5%
  • THERAMETRICS0.07 CHF-53.3%

No liability assumed, Date: 31.08.2014